Literature DB >> 3954935

Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity.

M J Ramond, E Comoy, D Lebrec.   

Abstract

Isoprenaline sensitivity and plasma catecholamine concentrations were studied to assess the sympathetic nervous activity in 13 patients with alcoholic cirrhosis and were compared with five controls. In patients with cirrhosis, the dose of isoprenaline required to increase the resting heart rate by 25 beats min-1 (chronotropic dose 25 or CD25) ranged from 2.50 to 34.73 micrograms (median: 4.47 micrograms) and was significantly higher than in controls (range: 0.66 to 2.76 micrograms, median: 1.34 micrograms). In cirrhotic patients, CD25 values were significantly correlated with plasma albumin concentration, resting heart rate and wedged hepatic venous pressure. In patients with cirrhosis, plasma noradrenaline concentrations ranged from 192 to 978 pg ml-1 (median: 444 pg ml-1) and adrenaline concentrations ranged from 5 to 183 pg ml-1 (median: 47 pg ml-1). No correlation was found between noradrenaline or adrenaline concentrations and CD25 values in cirrhotic patients. In conclusion, in patients with cirrhosis, beta-adrenoceptor responsiveness assessed by isoprenaline sensitivity is altered.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3954935      PMCID: PMC1400911          DOI: 10.1111/j.1365-2125.1986.tb05174.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  A COMPARISON OF THE EFFECTS OF ISOPROTERENOL IN THE NORMAL AND ASTHMATIC SUBJECT. A PRELIMINARY REPORT.

Authors:  D U COOKSON; C E REED
Journal:  Am Rev Respir Dis       Date:  1963-11

2.  The cardiac output at rest in Laennec's cirrhosis.

Authors:  H J KOWALSKI; W H ABELMANN
Journal:  J Clin Invest       Date:  1953-10       Impact factor: 14.808

Review 3.  Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors.

Authors:  R J Lefkowitz; M G Caron; G L Stiles
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

4.  Assessment of beta-adrenergic blockade with propranolol in patients with cirrhosis.

Authors:  E Bercoff; C Bataille; A E Pariente; D Valla; B Delhotal; D Lebrec
Journal:  Hepatology       Date:  1984 May-Jun       Impact factor: 17.425

5.  Cardiac sensitivity to isoprenaline, lymphocyte beta-adrenoceptors and age.

Authors:  D Fitzgerald; V Doyle; J G Kelly; K O'Malley
Journal:  Clin Sci (Lond)       Date:  1984-06       Impact factor: 6.124

6.  Hemodynamic changes in patients with portal venous obstruction.

Authors:  D Lebrec; C Bataille; E Bercoff; D Valla
Journal:  Hepatology       Date:  1983 Jul-Aug       Impact factor: 17.425

7.  [Systemic circulatory hyperkinetic syndrome in patients with cirrhosis. Relation with hepatocellular failure and portal hypertension].

Authors:  D Valla; T Poynard; E Bercoff; C Bataille; G Goldfarb; D Lebrec
Journal:  Gastroenterol Clin Biol       Date:  1984-04

8.  Role of the splanchnic bed in extracting circulating adrenaline and noradrenaline in normal subjects and in patients with cirrhosis of the liver.

Authors:  U Keller; P P Gerber; F R Bühler; W Stauffacher
Journal:  Clin Sci (Lond)       Date:  1984-07       Impact factor: 6.124

9.  Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension.

Authors:  J Vorobioff; J E Bredfeldt; R J Groszmann
Journal:  Am J Physiol       Date:  1983-01

Review 10.  Sympathetic nervous activity in cirrhosis. A survey of plasma catecholamine studies.

Authors:  J H Henriksen; H Ring-Larsen; N J Christensen
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

View more
  14 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

2.  Effect of meal induced splanchnic arterial vasodilatation on renal arterial haemodynamics in normal subjects and patients with cirrhosis.

Authors:  T Iwao; K Oho; R Nakano; M Yamawaki; T Sakai; M Sato; Y Miyamoto; A Toyonaga; K Tanikawa
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

3.  Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.

Authors:  Seyed Ali Gaskari; Hongqun Liu; Leila Moezi; Yang Li; Soon Koo Baik; Samuel S Lee
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 4.  Autonomic dysfunction in chronic liver disease.

Authors:  M T Hendrickse; D R Triger
Journal:  Clin Auton Res       Date:  1993-08       Impact factor: 4.435

Review 5.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

6.  Altered adenylyl cyclase activities and G-protein abnormalities in portal hypertensive rabbits.

Authors:  P A Cahill; Y Wu; J V Sitzmann
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 7.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

Review 8.  Cardiac abnormalities in liver cirrhosis.

Authors:  S S Lee
Journal:  West J Med       Date:  1989-11

Review 9.  Cirrhotic cardiomyopathy.

Authors:  Luis Ruiz-del-Árbol; Regina Serradilla
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

10.  Liver cirrhosis prevents atrial fibrillation: A reality or just an illusion?

Authors:  Mahmood Zamirian; Tahmineh Sarmadi; Kamran Aghasadeghi; Mohammad Bagher Sharif Kazemi
Journal:  J Cardiovasc Dis Res       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.